New lupus drug candidate enters first human tests

NCT ID NCT06576271

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called GSK4527363 in healthy volunteers and people with active lupus or lupus-related lung disease. The main goal is to check safety and how the body handles the drug. Around 142 participants will take part across four groups, including people of Chinese and Japanese descent.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK4527363
What this could lead to: If this early trial shows the drug is safe, it could lead to a new treatment option for people with lupus and related lung disease.
What could go wrong: This is a very early Phase 1 study with only 142 participants. The drug may not be safe or effective, and many early-stage drugs never make it to approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

connective tissue disorder interstitial lung disease systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

GSK Investigational Site
WITHDRAWN

Scottsdale, Arizona, 85260, United States
GSK Investigational Site
RECRUITING

Aurora, Colorado, 80045, United States
GSK Investigational Site
RECRUITING

Las Vegas, Nevada, 89154, United States
GSK Investigational Site
RECRUITING

Columbus, Ohio, 44109, United States
GSK Investigational Site
WITHDRAWN

Oklahoma City, Oklahoma, 73104, United States
GSK Investigational Site
WITHDRAWN

Dallas, Texas, 75390, United States
GSK Investigational Site
RECRUITING

Buenos Aires, C1280AEB, Argentina
GSK Investigational Site
RECRUITING

Rosario, S2002, Argentina
GSK Investigational Site
RECRUITING

San Juan Bautista, B1888AAE, Argentina
GSK Investigational Site
RECRUITING

San Miguel de Tucumán, T4000IHE, Argentina
GSK Investigational Site
RECRUITING

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
GSK Investigational Site
RECRUITING

Juiz de Fora, 36010-570, Brazil
GSK Investigational Site
RECRUITING

Porto Alegre, 90480000, Brazil
GSK Investigational Site
RECRUITING

Salvador, 40050-410, Brazil
GSK Investigational Site
RECRUITING

Bydgoszcz, 85-065, Poland
GSK Investigational Site
RECRUITING

Krakow, 30-688, Poland
GSK Investigational Site
RECRUITING

Poznan, 61-848, Poland
GSK Investigational Site
RECRUITING

Warsaw, 02-665, Poland
GSK Investigational Site
RECRUITING

Wroclaw, 50-556, Poland
GSK Investigational Site
RECRUITING

Barcelona, 08916, Spain
GSK Investigational Site
RECRUITING

Bilbao, 48013, Spain
GSK Investigational Site
RECRUITING

Pamplona, 31008, Spain
GSK Investigational Site
RECRUITING

Sabadell Barcelona, 08208, Spain
GSK Investigational Site
RECRUITING

Valladolid, 47012, Spain
GSK Investigational Site
RECRUITING

Cambridge, CB2 0GG, United Kingdom
GSK Investigational Site
RECRUITING

Liverpool, L7 8YE, United Kingdom
GSK Investigational Site
RECRUITING

London, SW3 6HP, United Kingdom
GSK Investigational Site
RECRUITING

Middlesex, HA1 3UJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.